Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.24.35 (matrix metalloproteinase 9)
 2,207 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Perfluorooctane sulfonate (PFOS), an ubiquitous environmental pollutant, has been associated with male reproductive disorders. However, the underlying mechanisms are not yet fully understood. In this study, in vivo and in vitro models were used to explore the effects of PFOS on blood-testis barrier (BTB) and related molecular mechanisms. First, male ICR mice were orally administrated PFOS (0.5-10mg/kg/bw) for 4 weeks. Bodyweight, sperm count, BTB integrity and the expression of proteins including p38 mitogen-activated protein kinase (MAPK), activating transcription factor 2 (ATF2), matrix metalloproteinase 9 (MMP9), tissue inhibitor of metalloproteinase 1(TIMP1) and BTB related junction proteins were evaluated. Furthermore, mouse primary Sertoli cells were used to delineate the molecular mechanisms that mediate the effects of PFOS on BTB. Our results demonstrated that PFOS dose-dependently increased BTB permeability, p38/ATF2 phosphorylation and MMP9 expression, paralleled by decrease in BTB junction protein Occludin and Connexin43 expression. Additionally, similar to the in vivo results, treatment of PFOS time-dependently increased Sertoli cell-based BTB permeability, phosphorylated-p38/ATF2 level, translocation of ATF2 into the nucleus and MMP9 expression/activity, paralleled by decrease in Occludin and Connexin43 expression. Meanwhile, inhibition of p38 by SB203580, knockdown of ATF2, or inhibition of MMP9 was sufficient to reduce the effects of PFOS on the Sertoli cell BTB. As such, the present study highlights a role of the p38/ATF2/MMP9 signaling pathway in PFOS-induced BTB disruption, advancing our understanding of molecular mechanisms for PFOS-induced male reproductive disorders.
 ...
PMID:Perfluorooctane sulfonate (PFOS) disrupts blood-testis barrier by down-regulating junction proteins via p38 MAPK/ATF2/MMP9 signaling pathway. 2781 24

The aim of this study was to investigate whether Cyclosporine A (CsA) attenuates early brain injury by alleviating matrix metalloproteinase 9 (MMP-9) associated blood-brain barrier (BBB) disruption after subarachnoid hemorrhage (SAH). A standard intravascular perforation model was used to produce the experimental SAH in C57B6J mice. Dosages of 5mg/kg, 10mg/kg and 15mg/kg CsA were evaluated for effects on neurological score, brain water content, Evans blue extravasation and fluorescence, P-p65, MMP-9 and BBB components' alterations after SAH. We found that CsA 15mg/kg is effective in attenuating BBB disruption, lowering edema, and improving neurological outcomes. In addition, Collagen IV, ZO-1, Occludin and Claudin 5 expressions in ipsilateral/left hemisphere were downregulated after SAH, but increased after CsA treatment. Our results suggest that CsA exert a neuroprotective role in SAH pathophysiology, possibly by alleviating MMP-9 associated BBB disruption.
 ...
PMID:Cyclosporine A alleviated matrix metalloproteinase 9 associated blood-brain barrier disruption after subarachnoid hemorrhage in mice. 2837 92